摘要
目的研究瑞舒伐他汀辅助无创正压通气对AECOPD患者肺部通气功能、SGRQ评分及C反应蛋白的影响。方法选择2015年1月至2016年6月在我院接受治疗的118例AECOPD患者。随机分为对照组和观察组,每组59例,对照组给予无创正压通气联合AECOPD常规治疗,观察组在对照组的基础上加用瑞舒伐他汀。比较两组患者的肺功能、SGRQ评分和C反应蛋白水平。结果治疗前两组患者的肺功能比较差异无统计学意义(P>0.05),治疗后两组患者的FEV1、FVC和FEV1/FVC均明显上升,观察组患者的FEV1、FVC和FEV1/FVC高于对照组,差异有统计学意义(P<0.05)。治疗前两组患者的SGRQ评分比较差异无统计学意义(P>0.05),治疗后两组患者的活动能力、症状部分、疾病影响和SGRQ总分均明显下降,观察组患者的活动能力、症状部分、疾病影响和SGRQ总分低于对照组,差异有统计学意义(P<0.05)。治疗前对照组患者的CRP水平为(20.36±9.31)mg/dL,观察组患者的CRP水平为(20.55±9.27)mg/dL,两组患者比较差异无统计学意义(P>0.05);治疗后对照组和观察组的CRP水平分别为(13.63±7.14)、(8.26±4.37)mg/dL,观察组明显低于对照组,差异有统计学意义(P<0.05)。结论瑞舒伐他汀辅助无创正压通气,可以明显改善AECOPD患者的肺功能,缓解体内炎症反应,提高生活质量。
Objective To study the effects of rosuvastatin-assisted noninvasive positive pressure ventilation on pulmonary ventilation function,SGRQ scores and CRP level in patients with AECOPD.Methods Totally 118 patients with AECOPD treated in our hospital from January 2015 to June 2016 were selected and randomly divided into control group（n=59） and observation group（n=59）.Control group was treated with noninvasive positive pressure ventilation combined with AECOPD conventional treatment,and observation group was treated with rosuvastatin on the basis of treatment for control group.The lung function,SGRQ score and CRP level between the two groups were compared.Results Before treatment,the pulmonary function of two groups showed no significant difference（P0.05）;after treatment,the FEV1,FVC and FEV1/FVC of the two groups were significantly increased,which were higher in observation group than those of control group,there being significant difference between the two groups（P0.05）.The SGRQ score of the two groups had no significant difference before treatment（P0.05）,but the activity,some of the symptoms,impact of the disease and the SGRQ total score of the two groups were significantly decreased after treatment,which in observation group were lower than those of control group,there being significant difference between the two groups（P0.05）.Before treatment,the CRP level of control group was（20.36 ±9.31） mg/dL,and in observation group it was（20.55±9.27） mg/dL,there being no significant difference between the two groups（P0.05）;after treatment,the CRP level of control group and observation group were（13.63±7.14） mg/dL and（8.26±4.37）mg/dL,respectively,observation group being significant lower than control group,there being significant difference between the two groups（P0.05）.Conclusion Rosuvastatin-assisted noninvasive positive pressure ventilation can significantly improve lung function in patients with AECOPD alleviate inflammation in the body and improve the quality of life.
出处
《实用药物与临床》
CAS
2017年第3期265-267,共3页
Practical Pharmacy and Clinical Remedies
基金
广西自然科学基金项目(2012GXNSFAA053095)
